What is AOD-9604 studied for?

Published and ongoing research looks at lipolysis and fat oxidation in animal and cell models; human obesity trials that failed their primary endpoints; cartilage and joint models. These are areas of study, not promised outcomes.

Is AOD-9604 FDA-approved?

AOD-9604 has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.

How is AOD-9604 typically used?

Frequently marketed on mechanism rather than on results The human evidence for weight loss is genuinely negative, not merely thin Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.

What are the risks and unknowns with AOD-9604?

Research use only; not FDA-approved Safety profile appeared benign in trials, but so did efficacy

Metabolic & body composition

AOD-9604

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending.

A fragment of human growth hormone studied for fat metabolism without the growth-signaling effects of full HGH.

What it is

AOD-9604 corresponds to the C-terminal fragment of human growth hormone thought to carry its lipolytic activity. It was developed as an anti-obesity candidate specifically because it does not appear to raise IGF-1 or affect glucose the way full HGH does. Human trials did not show meaningful weight loss versus placebo.

What it's studied for

Lipolysis and fat oxidation in animal and cell models
Human obesity trials that failed their primary endpoints
Cartilage and joint models

How it's used in practice

Frequently marketed on mechanism rather than on results
The human evidence for weight loss is genuinely negative, not merely thin

What you should know before asking about it

Research use only; not FDA-approved
Safety profile appeared benign in trials, but so did efficacy

Frequently asked questions.

What is AOD-9604?: AOD-9604 corresponds to the C-terminal fragment of human growth hormone thought to carry its lipolytic activity. It was developed as an anti-obesity candidate specifically because it does not appear to raise IGF-1 or affect glucose the way full HGH does. Human trials did not show meaningful weight loss versus placebo.
What is AOD-9604 studied for?: Published and ongoing research looks at lipolysis and fat oxidation in animal and cell models; human obesity trials that failed their primary endpoints; cartilage and joint models. These are areas of study, not promised outcomes.
Is AOD-9604 FDA-approved?: AOD-9604 has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
How is AOD-9604 typically used?: Frequently marketed on mechanism rather than on results The human evidence for weight loss is genuinely negative, not merely thin Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
What are the risks and unknowns with AOD-9604?: Research use only; not FDA-approved Safety profile appeared benign in trials, but so did efficacy

Sources

1.Published literature on AOD-9604— PubMed, U.S. National Library of Medicine
2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
4.Test directory and patient service center locator— Quest Diagnostics

About this page

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.

This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.

Begin your intake Peptide therapy overview

Single Regulator (GLP-1) — semaglutide

Semaglutide, listed as Single Regulator (GLP-1) because compounded formulations cannot be marketed under the drug's commercial name. A GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.

Dual Regulator (GLP-1/GIP) — tirzepatide

Tirzepatide, listed as Dual Regulator (GLP-1/GIP) because compounded formulations cannot be marketed under the drug's commercial name. A GIP/GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.

Triple Regulator (GLP-1/GIP/glucagon)

An investigational triple agonist (GLP-1, GIP and glucagon) in late-stage clinical trials — not approved, not prescribable.

View the full peptide library